These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

976 related articles for article (PubMed ID: 33550043)

  • 21. Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs.
    Chopra D; Boparai JK; Bhandari B; Srivastava A; Gupta R
    Infect Disord Drug Targets; 2021; 21(7):e160921189260. PubMed ID: 33342420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.
    Cao M; Su X; Jiang S
    Stem Cell Reports; 2021 Mar; 16(3):398-411. PubMed ID: 33691145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2.
    Kivrak A; Ulaş B; Kivrak H
    Int Immunopharmacol; 2021 Jan; 90():107232. PubMed ID: 33290969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in management of COVID-19: A review.
    Mouffak S; Shubbar Q; Saleh E; El-Awady R
    Biomed Pharmacother; 2021 Nov; 143():112107. PubMed ID: 34488083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
    Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
    SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.
    Gudadappanavar AM; Benni J
    J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
    van de Leemput J; Han Z
    Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins.
    Ansari MA; Alomary MN; Jamal QMS; Almoshari Y; Salawi A; Almahmoud SA; Khan J
    Curr Pharm Des; 2022; 28(46):3706-3719. PubMed ID: 36278465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
    Rizk JG; Forthal DN; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Pfeiffer JP; Lewin JC
    Drug Discov Today; 2021 Feb; 26(2):593-603. PubMed ID: 33253920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyanorona-20: The first potent anti-SARS-CoV-2 agent.
    Rabie AM
    Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.
    Maciorowski D; Ogaugwu C; Durvasula SR; Durvasula R; Kunamneni A
    SLAS Discov; 2021 Mar; 26(3):311-329. PubMed ID: 33319627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.
    Lowe DM; Brown LK; Chowdhury K; Davey S; Yee P; Ikeji F; Ndoutoumou A; Shah D; Lennon A; Rai A; Agyeman AA; Checkley A; Longley N; Dehbi HM; Freemantle N; Breuer J; Standing JF;
    PLoS Med; 2022 Oct; 19(10):e1004120. PubMed ID: 36260627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
    Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
    JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of repurposed drugs on the symptomatic COVID-19 patients.
    Hussain I; Hussain A; Alajmi MF; Rehman MT; Amir S
    J Infect Public Health; 2021 Jan; 14(1):24-38. PubMed ID: 33341481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective.
    Shahverdi M; Darvish M
    Curr Mol Med; 2021; 21(7):562-572. PubMed ID: 33272178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.
    Kumari M; Lu RM; Li MC; Huang JL; Hsu FF; Ko SH; Ke FY; Su SC; Liang KH; Yuan JP; Chiang HL; Sun CP; Lee IJ; Li WS; Hsieh HP; Tao MH; Wu HC
    J Biomed Sci; 2022 Sep; 29(1):68. PubMed ID: 36096815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
    Fiscon G; Conte F; Farina L; Paci P
    PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.
    Yang X; Liu Y; Liu Y; Yang Q; Wu X; Huang X; Liu H; Cai W; Ma G
    Expert Rev Clin Pharmacol; 2020 Sep; 13(9):957-975. PubMed ID: 32746653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.